cowtown jay
23 hours ago
Hi, eb!
In college, I discovered that my interests were in political science and economics. I wasn't particularly happy to make that discovery, because I couldn't imagine a more frustrating career choice than being a political economist. So I never tried to go to law school. But I could not shake my motivation to fight against the abuse of discretionary authority by unelected government bureaucrats. I was honored to have been asked by SpongeTech's bankruptcy trustee to become the Estate Representative for shareholders in that company. In that capacity, I subpoenaed Electronic Blue Sheet trading records from FINRA which showed the continuous Naked Short selling of tens of millions of shares in that company everyday, despite FTD short sell restrictions, all the while until trading was finally halted. That effort proved for naught, as the bankruptcy judge recognized that shareholders had a case, but he could not see how the naked short selling impacted the company.
In Humanigen's case, the SEC has largely hidden their abuse of discretionary authority, since the case was sealed. But, Humanigen being a biotech, there is a plethora of other government agencies shown abusing their discretionary authority, such as NIAID, the NIH, the FDA, the CDC, the DOJ, and still, the SEC, to an extent that is known. The most promising appointment in this new Administration, for my purposes. is that of RFK, Jr., as the head of the HHS. I hope he will expose the real toll of the harm our present course is extracting by our national covid response, to include the significant number of excess deaths being reported since the pandemic.
Somewhat ironically, a research report titled 'Mortality Trends Among Early Adults in the United States, 1999-2023,' was just published by the JAMA Network. I say it's ironic, because it was funded, in part, by a grant established by Bobby's Aunt Ethel's foundation.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829783
The Report notes, "Early adult excess mortality was 34.6% higher than expected in 2019 and then further accelerated during the COVID-19 pandemic. In 2021, all-cause excess mortality was nearly 3 times what it had been in 2019 (116.2 vs 41.7 deaths per 100?000 population). In 2023, excess mortality decreased, but only to approximately midway between its 2019 and 2021 levels (79.1 deaths per 100?000 population). As a result, early adult mortality was 70.0% higher in 2023 than it would have been had pre-2011 trends continued, reflecting 71?124 excess deaths."
I've previously linked mortality data from other studies that are pretty much in-line, showing excess deaths that are >80% higher than expected, That's why I believe we are seeing tens of millions of preventable deaths. I think Lenzilumab could help restore the immune system in these post pandemic 1, and in pre-pandemic 2 populations.
Gator44
1 month ago
Was shareholder of HGEN back during covid madness. Respect the knowledge on this board. SANA opinion needed on Type 1 diabetes PR:
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
January 07, 2025 16:05 ET
| Source: Sana Biotechnology, Inc
Share
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression
Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes
Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT)
MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation
Study Continues to Evaluate Safety, Persistence, and Function of Transplanted Cells
Conference Call to be Webcast at 1:30pm PT
SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study was conducted in partnership with Uppsala University Hospital. Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase with a mixed meal tolerance test (MMTT), consistent with insulin secretion in response to a meal. MRI scanning also demonstrated a sustained signal at the site of transplanted cells over time, which is consistent with graft survival. The study identified no safety issues, and the HIP-modified islet cells evaded immune responses.
“These initial exciting results build upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana. The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic islet cell transplantation in type 1 diabetes with no immunosuppression,” said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. “In type 1 diabetes, a person’s immune system attacks and destroys the beta cells. Today’s data, when combined with progress elsewhere in the field, provide real hope that a scalable, curative treatment for patients with type 1 diabetes, meaning normal blood glucose with no insulin injections or immunosuppression, is possible. We look forward to longer follow-up and plan to submit study results for publication as well as for presentation at an upcoming scientific forum.”
“We achieved our goals for the study, identifying no safety issues as well as demonstrating survival, function, and evasion of immune detection of HIP-modified primary pancreatic islet cells transplanted intramuscularly with no immunosuppression,” said Steve Harr, Sana’s President and Chief Executive Officer. “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual. Safe cell transplantation without immunosuppression has the potential to transform the treatment of type 1 diabetes and a number of other diseases. We view the insights from the current study as directly applicable to developing SC451, our HIP-modified, stem cell-derived pancreatic islet cell program for the treatment of type 1 diabetes. Thank you to everyone involved in this study.”
“These initial clinical results show that cell therapies that replace insulin-producing cells without immunosuppression are approaching reality as a meaningful and potentially life-changing cure for type 1 diabetes,” said Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D (previously known as JDRF). “We are proud to contribute to translational research endeavors such as those at Sana as a supporter and investor through the T1D Fund: A Breakthrough T1D Venture. We are extremely grateful for the collaborative efforts of the research teams at Sana, at Uppsala University Hospital, and all those involved, for their dedication to this work. We look forward to working with Sana and others to break down the remaining barriers to ensure all members of the T1D community can benefit from these life-changing breakthroughs.”
Primary islet cell transplantation with immunosuppression is an established procedure in type 1 diabetes in which allogeneic pancreatic islet cells are isolated from a deceased donor’s pancreas and transplanted into a patient with a goal of normal blood glucose control and insulin independence. As with whole-organ transplants, suppression of the recipient’s immune system has historically been required to prevent immune rejection of the allogeneic transplanted cells and resurgence of the inciting autoimmune attack. Sana’s HIP technology is designed to overcome immunologic rejection of allogeneic cells, and in type 1 diabetes, also to evade the autoimmune rejection of pancreatic beta cells. UP421 cells were transplanted with no immunosuppression, and the survival of the islet cells provides evidence that these cells evade both allogeneic and autoimmune detection.
Webcast Conference Call Information
Sana will host a webcast conference call to discuss results today, January 7, 2025 at 1:30 p.m. PT. The live webcast and audio archive of the presentation will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. The call can be accessed by dialing (877)-346-6112 (domestic) or (848)-280-6350 (international) and referring to conference ID 9582416.
About the Uppsala University Hospital Investigator-Sponsored Study of UP421 in Type 1 Diabetes
The investigator-sponsored study of UP421 is supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust. The study tests the hypothesis whether HIP-engineered insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without need of simultaneous treatment with immunosuppressive medicines. To do this, UP421 is engineered using Sana’s HIP platform at Oslo University Hospital. The study involves intramuscular surgical transplantation of primary, or donor-derived, HIP-engineered islet cells into the forearm of patients with type 1 diabetes. The primary objective of the study is to investigate safety of UP421 transplantation in patients with type 1 diabetes, with secondary endpoints including cell survival, immune evasion, and C-peptide production. Circulating C-peptide is a measure of endogenous insulin production. This first-in-human study examines a low dose of HIP-modified primary islets to initially establish the safety and function of HIP-modified islets without immunosuppression and, as a result, is not intended to show improvement in glycemia and/or reduction in exogenous insulin administration.
Results of the study over four weeks after islet cell transplantation demonstrate the survival and function of pancreatic beta cells at each weekly blood draw, as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase during an MMTT, consistent with insulin secretion in response to a meal. At baseline, the patient had undetectable C-peptide both fasting and during an MMTT. MRI scanning demonstrated a sustained signal at the site of the graft over time, consistent with graft survival. The HIP platform has achieved proof-of-concept in humans, showing evasion of immune recognition with the potential broad application for allogeneic transplantation without immunosuppression.
About the Sana Biotechnology Hypoimmune (HIP) Platform
Sana’s HIP platform is designed to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression. We are applying the HIP technology to develop therapeutic candidates at scale, including pluripotent stem cells, which can then be differentiated into multiple cell types, including pancreatic islet cells, and donor-derived allogeneic CAR T cells. We and our collaborators have generated significant foundational intellectual property in the area. Early clinical data from Phase 1 trials and preclinical data published in peer-reviewed journals demonstrate across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arms of the immune system while retaining their activity. Sana’s most advanced programs utilizing this platform include stem cell-derived pancreatic islet cells for patients with type 1 diabetes, an allogeneic CAR T program for B-cell mediated autoimmune diseases, and an allogeneic CAR T program targeting CD22+ cancers.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, and Bothell, WA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its preclinical, clinical and regulatory development plans and timing expectations; the ability of Sana’s HIP platform to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression and, in type 1
Gator44
1 month ago
Was shareholder of HGEN back during covid madness. Respect the knowledge on this board. SANA opinion needed on Type 1 diabetes PR:
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
January 07, 2025 16:05 ET
| Source: Sana Biotechnology, Inc
Share
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression
Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes
Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT)
MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation
Study Continues to Evaluate Safety, Persistence, and Function of Transplanted Cells
Conference Call to be Webcast at 1:30pm PT
SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study was conducted in partnership with Uppsala University Hospital. Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase with a mixed meal tolerance test (MMTT), consistent with insulin secretion in response to a meal. MRI scanning also demonstrated a sustained signal at the site of transplanted cells over time, which is consistent with graft survival. The study identified no safety issues, and the HIP-modified islet cells evaded immune responses.
“These initial exciting results build upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana. The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic islet cell transplantation in type 1 diabetes with no immunosuppression,” said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. “In type 1 diabetes, a person’s immune system attacks and destroys the beta cells. Today’s data, when combined with progress elsewhere in the field, provide real hope that a scalable, curative treatment for patients with type 1 diabetes, meaning normal blood glucose with no insulin injections or immunosuppression, is possible. We look forward to longer follow-up and plan to submit study results for publication as well as for presentation at an upcoming scientific forum.”
“We achieved our goals for the study, identifying no safety issues as well as demonstrating survival, function, and evasion of immune detection of HIP-modified primary pancreatic islet cells transplanted intramuscularly with no immunosuppression,” said Steve Harr, Sana’s President and Chief Executive Officer. “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual. Safe cell transplantation without immunosuppression has the potential to transform the treatment of type 1 diabetes and a number of other diseases. We view the insights from the current study as directly applicable to developing SC451, our HIP-modified, stem cell-derived pancreatic islet cell program for the treatment of type 1 diabetes. Thank you to everyone involved in this study.”
“These initial clinical results show that cell therapies that replace insulin-producing cells without immunosuppression are approaching reality as a meaningful and potentially life-changing cure for type 1 diabetes,” said Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D (previously known as JDRF). “We are proud to contribute to translational research endeavors such as those at Sana as a supporter and investor through the T1D Fund: A Breakthrough T1D Venture. We are extremely grateful for the collaborative efforts of the research teams at Sana, at Uppsala University Hospital, and all those involved, for their dedication to this work. We look forward to working with Sana and others to break down the remaining barriers to ensure all members of the T1D community can benefit from these life-changing breakthroughs.”
Primary islet cell transplantation with immunosuppression is an established procedure in type 1 diabetes in which allogeneic pancreatic islet cells are isolated from a deceased donor’s pancreas and transplanted into a patient with a goal of normal blood glucose control and insulin independence. As with whole-organ transplants, suppression of the recipient’s immune system has historically been required to prevent immune rejection of the allogeneic transplanted cells and resurgence of the inciting autoimmune attack. Sana’s HIP technology is designed to overcome immunologic rejection of allogeneic cells, and in type 1 diabetes, also to evade the autoimmune rejection of pancreatic beta cells. UP421 cells were transplanted with no immunosuppression, and the survival of the islet cells provides evidence that these cells evade both allogeneic and autoimmune detection.
Webcast Conference Call Information
Sana will host a webcast conference call to discuss results today, January 7, 2025 at 1:30 p.m. PT. The live webcast and audio archive of the presentation will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. The call can be accessed by dialing (877)-346-6112 (domestic) or (848)-280-6350 (international) and referring to conference ID 9582416.
About the Uppsala University Hospital Investigator-Sponsored Study of UP421 in Type 1 Diabetes
The investigator-sponsored study of UP421 is supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust. The study tests the hypothesis whether HIP-engineered insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without need of simultaneous treatment with immunosuppressive medicines. To do this, UP421 is engineered using Sana’s HIP platform at Oslo University Hospital. The study involves intramuscular surgical transplantation of primary, or donor-derived, HIP-engineered islet cells into the forearm of patients with type 1 diabetes. The primary objective of the study is to investigate safety of UP421 transplantation in patients with type 1 diabetes, with secondary endpoints including cell survival, immune evasion, and C-peptide production. Circulating C-peptide is a measure of endogenous insulin production. This first-in-human study examines a low dose of HIP-modified primary islets to initially establish the safety and function of HIP-modified islets without immunosuppression and, as a result, is not intended to show improvement in glycemia and/or reduction in exogenous insulin administration.
Results of the study over four weeks after islet cell transplantation demonstrate the survival and function of pancreatic beta cells at each weekly blood draw, as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase during an MMTT, consistent with insulin secretion in response to a meal. At baseline, the patient had undetectable C-peptide both fasting and during an MMTT. MRI scanning demonstrated a sustained signal at the site of the graft over time, consistent with graft survival. The HIP platform has achieved proof-of-concept in humans, showing evasion of immune recognition with the potential broad application for allogeneic transplantation without immunosuppression.
About the Sana Biotechnology Hypoimmune (HIP) Platform
Sana’s HIP platform is designed to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression. We are applying the HIP technology to develop therapeutic candidates at scale, including pluripotent stem cells, which can then be differentiated into multiple cell types, including pancreatic islet cells, and donor-derived allogeneic CAR T cells. We and our collaborators have generated significant foundational intellectual property in the area. Early clinical data from Phase 1 trials and preclinical data published in peer-reviewed journals demonstrate across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arms of the immune system while retaining their activity. Sana’s most advanced programs utilizing this platform include stem cell-derived pancreatic islet cells for patients with type 1 diabetes, an allogeneic CAR T program for B-cell mediated autoimmune diseases, and an allogeneic CAR T program targeting CD22+ cancers.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, and Bothell, WA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its preclinical, clinical and regulatory development plans and timing expectations; the ability of Sana’s HIP platform to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of allogeneic cells without the need for immunosuppression and, in type 1 diabetes, enable transplanted islet cells to avoid immune rejection and produce insulin without immunosuppression; the potential implications of the data on the ability to find a scalable, curative treatment for patients with type 1 diabetes; expectations with respect to follow up and publication and presentation of the study results; the potential safety and survival, function, and evasion of immune detection of HIP-modified primary pancreatic islet cells transplanted intramuscularly with no immunosuppression; the potential of safe cell transplantation without immunosuppression to transform the treatment of type 1 diabetes and a number of other diseases; the potential application of the learnings from the study to the company’s SC451 program; the potential significance of the survival of the islet cells in the study; and the ability to apply the HIP technology to develop therapeutic candidates at scale, including both pluripotent stem cells and donor-derived allogeneic CAR T cells. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s Securities and Exchange Commission (SEC) reports, including but not limited to its Quarterly Report on Form 10-Q dated November 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
Rich Allan, FGS Global
503-851-0807
rich.allan@fgsglobal.com
Company Profile
Sana Biotechnology, Inc
Industry: Pharmaceuticals & Biotechnology
Website:
https://sana.com
Press Release Actions
Print
Download PDF
Subscribe via RSS
Subscribe via ATOM
Javascript
Recommended Reading
January 08, 2025 16:05 ET
Source:
Sana Biotechnology, Inc
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology to Present at the 43rd Annual J...
December 02, 2024 09:00 ET
Source:
Sana Biotechnology, Inc
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including...
Sana Biotechnology Announces Fast Track...
Explore
GlobeNewswire
About Us
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
Follow us on social media:
Global News
English
Français
Deutsch
Newswire Distribution Network & Management
Home
Newsroom
RSS Feeds
Notified
Legal
Contact us
Resources
News
Market Data
Register to chat with like-minded investors on our interactive forums.
Ask ADVFN Intelligence (AI)
DTGoody
3 days ago
